Evolutionary Genomics, Inc. (FNAM)
USD 0.0
(0.0%)
USD 0.0
(0.0%)
| Breakdown | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | -640.94 Thousand | -1.58 Million | -2.29 Million | -625.98 Thousand | -748.83 Thousand | -1.17 Million |
| Net Income | -1.93 Million | -2.79 Million | -1.71 Million | -793.14 Thousand | -1.09 Million | -539.61 Thousand |
| Depreciation & Amortization | 1.02 Million | 1.03 Million | 409.36 Thousand | 40.72 Thousand | 41.07 Thousand | 42.85 Thousand |
| Deferred income taxes | -2.07 Million | - | -987.35 Thousand | 31.9 Thousand | - | -530.23 Thousand |
| Stock-based compensation | 193.2 Thousand | 219.71 Thousand | 219.71 Thousand | 55.82 Thousand | 98.57 Thousand | 101.89 Thousand |
| Change in working capital | 79.31 Thousand | 35.66 Thousand | -46.98 Thousand | 52.19 Thousand | -52.38 Thousand | -556.02 Thousand |
| Other non-cash items | 2.07 Million | -83.39 Thousand | -180.18 Thousand | -13.49 Thousand | 262.51 Thousand | -226.41 Thousand |
| Investing Cash Flow | - | - | 147.61 Thousand | - | - | - |
| Investments in PPE | -3.00 | - | - | - | - | - |
| Acquisitions | - | - | - | - | - | - |
| Investment purchases | - | - | - | - | - | - |
| Sales/Maturities of investments | - | - | 147.61 Thousand | - | - | - |
| Other Investing Activities | - | - | 147.61 | - | - | - |
| Financing Cash Flow | 1 Million | 1.58 Million | 2.32 Million | 540.01 Thousand | -242.36 Thousand | -242.36 Thousand |
| Debt repayment | - | -1.58 Million | -2.32 Million | - | - | - |
| Dividends payments | - | - | - | - | -242.36 Thousand | -242.36 Thousand |
| Common Stock Repurchased | - | - | - | - | - | - |
| Common Stock Issuance | 1 Million | - | - | 540.01 Thousand | - | - |
| Other Financing Activities | 1 Million | 3.16 Million | 4.9 Million | 269.37 Thousand | 242.36 Thousand | 242.36 Thousand |
| Accounts receivables | - | - | 6845.00 | 33.59 Thousand | -40.43 Thousand | 9289.00 |
| Accounts payables | 159.37 Thousand | 15.7 Thousand | -16.25 Thousand | 19.41 Thousand | -10.64 Thousand | -35.42 Thousand |
| Inventory | - | - | 16.25 Thousand | -19.41 Thousand | - | - |
| Other working capital | -80.05 Thousand | 19.96 Thousand | -53.82 Thousand | 18.6 Thousand | -11.94 Thousand | -565.31 Thousand |
| Cash at beginning of period | 214 Thousand | 215.83 Thousand | 45.44 Thousand | 131.4 Thousand | 880.24 Thousand | 2.05 Million |
| Cash at end of period | 577.06 Thousand | 214 Thousand | 215.83 Thousand | 45.44 Thousand | 131.4 Thousand | 880.24 Thousand |
| Capital Expenditure | -3.00 | - | - | - | - | - |
| Effect of forex changes on cash | - | - | - | - | - | - |
| Net cash flow / Change in cash | 363.05 Thousand | -1827.00 | 170.39 Thousand | -85.96 Thousand | -748.83 Thousand | -1.17 Million |
| Free Cash Flow | -640.95 Thousand | -1.58 Million | -2.29 Million | -625.98 Thousand | -748.83 Thousand | -1.17 Million |
| Breakdown | 2023 Q3 | 2023 Q2 | 2023 Q1 | 2022 Q4 | 2022 FY | 2022 Q3 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | - | - | - | - | - | - |
| Net Income | - | - | - | -333.75 Thousand | -1.93 Million | -545.27 Thousand |
| Depreciation & Amortization | - | - | - | 255.37 Thousand | 1.02 Million | 255.37 Thousand |
| Deferred income taxes | - | - | - | -471.41 Thousand | -2.07 Million | - |
| Stock-based compensation | - | - | - | -19.62 Thousand | 193.2 Thousand | 78.18 Thousand |
| Change in working capital | - | - | - | -90.48 Thousand | 79.31 Thousand | 79.48 Thousand |
| Other non-cash items | - | - | - | 471.41 Thousand | 2.07 Million | 64.68 Thousand |
| Investing Cash Flow | - | - | - | - | - | - |
| Investments in PPE | - | - | - | - | - | - |
| Acquisitions | - | - | - | - | - | - |
| Investment purchases | - | - | - | - | - | - |
| Sales/Maturities of investments | - | - | - | - | - | - |
| Other Investing Activities | - | - | - | - | - | - |
| Financing Cash Flow | - | - | - | -1 Million | 1 Million | - |
| Debt repayment | - | - | - | - | - | - |
| Dividends payments | - | - | - | - | - | - |
| Common Stock Repurchased | - | - | - | - | - | - |
| Common Stock Issuance | - | - | - | -550 Thousand | 1 Million | - |
| Other Financing Activities | - | - | - | -454 Thousand | 1 Million | - |
| Accounts receivables | - | - | - | - | - | - |
| Accounts payables | - | - | - | 19.71 Thousand | 159.37 Thousand | - |
| Inventory | - | - | - | - | - | - |
| Other working capital | - | - | - | -110.19 Thousand | -80.05 Thousand | 14.8 Thousand |
| Cash at beginning of period | - | - | 577.06 Thousand | 765.55 Thousand | 214 Thousand | 897.77 Thousand |
| Cash at end of period | - | - | 577.06 Thousand | 577.06 Thousand | 577.06 Thousand | 765.55 Thousand |
| Capital Expenditure | - | - | - | - | - | - |
| Effect of forex changes on cash | - | - | - | - | - | - |
| Net cash flow / Change in cash | - | - | - | -188.48 Thousand | 363.05 Thousand | -132.22 Thousand |
| Free Cash Flow | - | - | - | -188.48 Thousand | -640.94 Thousand | -132.22 Thousand |
INGERRAND
3369
600449
603787
MARGOFIN
ILST